帶狀疱疹治療原則與新型基因重組次單元疫苗介紹

New Herpes Zoster Recombinant Subunit Vaccine and Pharmacotherapy of Herpes Zoster

蔡謹如(Chin-Ju Tsai) ； 陳曦(Si Chen) ； 蔡宛真(Wan-Chen Tsai) ； 王詩涵(Shih-Han Wang)

《臺灣臨床藥學雜誌》 28卷2期 (2020/04) Pp. 77-84

https://doi.org/10.6168/FJCP.202004_28(2).0001

摘要

2017年10月Shingrix疫苗（HZ/su, GlaxoSmithKline Biologicals）於美國上市，其為基因重組次單元疫苗（recombinant subunit vaccine），且有新一代的佐劑和遞送系統，可以做為Zostavax疫苗（zoster virus vaccine）活性減毒帶狀疱疹疫苗的替代方案。Shingrix疫苗主要用來預防50歲以上之成人帶狀疱疹，整個療程共需肌肉注射兩劑，兩劑需間隔2~6個月，可以降低帶狀疱疹發生率及後續併發症風險，並且可以用於免疫功能不全的病患，對於曾施打過Zostavax疫苗者，5年後可以考慮施打Shingrix疫苗以獲得更好的保護效力。目前尚不清楚Shingrix疫苗於臺灣的上市時間，若有接種帶狀疱疹疫苗需求者，建議先接種Zostavax疫苗。

關鍵字

帶狀疱疹 ； 基因重組次單元疫苗 ； 帶狀疱疹疫苗

並列摘要

In October 2017, Shingrix vaccine (HZ/su, GlaxoSmithKline Biologicals) was launched in the US and is a recombinant subunit vaccine that has new generation adjuvants and delivery systems and can be an alternative to live-attenuated vaccine. Shingrix vaccine was approved primarily to prevent herpes zoster in ≥ 50-year-old adults. The entire treatment is via intramuscular injection (IM) of 2 doses and the interval between the two doses is 2-6 months, which can reduce the incidence of herpes zoster and the risk of subsequent complications. According to clinical trials, Shingrix vaccine could reduce the incidence of herpes zoster and the risk of complications, and it can be used in patients for immunosuppression. Furthermore, the person who accepts the Zostavax vaccine could consider re-inoculation after a 5-year period to get better protection effectiveness. However, timing of the launch of the Shingrix vaccine in Taiwan is currently unknown. If you have a need for a vaccination against herpes zoster, it is recommended that you first vaccinate using the existing vaccine, Zostavax vaccine.

並列關鍵字

Herpes Zoster ； Recombinant Subunit Vaccine ； Herpes Zoster Vaccine